A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate

Background:Owing to its role in cancer, the phosphoinositide 3-kinase (PI3K)/Akt pathway is an attractive target for therapeutic intervention. We previously reported that the inhibition of Akt by inositol 1,3,4,5,6-pentakisphosphate (InsP5) results in anti-tumour properties. To further develop this compound we modified its structure to obtain more potent inhibitors of the PI3K/Akt pathway.Methods:Cell proliferation/survival was determined by cell counting, sulphorhodamine or acridine orange/ethidium bromide assay; Akt activation was determined by western blot analysis. In vivo effect of compounds was tested on PC3 xenografts, whereas in vitro activity on kinases was determined by SelectScreen Kinase Profiling Service.Results:The derivative 2-O-benzyl-myo-inositol 1,3,4,5,6-pentakisphosphate (2-O-Bn-InsP5) is active towards cancer types resistant to InsP5 in vitro and in vivo. 2-O-Bn-InsP5 possesses higher pro-apoptotic activity than InsP5 in sensitive cells and enhances the effect of anti-cancer compounds. 2-O-Bn-InsP5 specifically inhibits 3-phosphoinositide-dependent protein kinase 1 (PDK1) in vitro (IC50 in the low nanomolar range) and the PDK1-dependent phosphorylation of Akt in cell lines and excised tumours. It is interesting to note that 2-O-Bn-InsP5 also inhibits the mammalian target of rapamycin (mTOR) in vitro.Conclusions:InsP5 and 2-O-Bn-InsP5 may represent lead compounds to develop novel inhibitors of the PI3K/Akt pathway (including potential dual PDK1/mTOR inhibitors) and novel potential anti-cancer drugs.

[1]  A. Newton,et al.  PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. , 2007, Molecular cell.

[2]  P Ubezio,et al.  Cell cycle effects of gemcitabine , 2001, International journal of cancer.

[3]  D. V. van Aalten,et al.  Novel inositol phospholipid headgroup surrogate crystallized in the pleckstrin homology domain of protein kinase Balpha. , 2007, ACS chemical biology.

[4]  M. Waterfield,et al.  Synthesis and function of 3-phosphorylated inositol lipids. , 2001, Annual review of biochemistry.

[5]  M. Broggini,et al.  Novel functional PI 3‐kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  C. Sessa,et al.  mTOR inhibitors in the treatment of cancer. , 2008, Expert opinion on investigational drugs.

[7]  S. Hewitt,et al.  Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt , 2006, Molecular Cancer Therapeutics.

[8]  Pier Paolo Pandolfi,et al.  The PTEN–PI3K pathway: of feedbacks and cross-talks , 2008, Oncogene.

[9]  J. Testa,et al.  AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival , 2002, Oncogene.

[10]  L. Cantley,et al.  Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.

[11]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[12]  A. Prescott,et al.  The in vivo role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knockin mutation , 2004, The EMBO journal.

[13]  P. Dennis,et al.  Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. , 2002, Molecular cancer therapeutics.

[14]  J E Paciga,et al.  Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. , 2001, Cancer research.

[15]  Elizabeth Iorns,et al.  Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. , 2009, The Biochemical journal.

[16]  A. Newton,et al.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. , 2005, Molecular cell.

[17]  Yan Shi,et al.  Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo , 2005, Molecular Cancer Therapeutics.

[18]  E. Sausville,et al.  Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. , 2003, Molecular cancer therapeutics.

[19]  P. Dennis,et al.  Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. , 2003, Journal of the American Chemical Society.

[20]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[21]  A. M. Riley,et al.  Regioselective hydrolysis of myo-inositol 1,3,5-orthobenzoate via a 1,2-bridged 2'-phenyl-1',3'-dioxolan-2'-ylium ion provides a rapid route to the anticancer agent Ins(1,3,4,5,6)P5. , 2006, Chemical communications.

[22]  R. Parsons,et al.  Hypomorphic Mutation of PDK1 Suppresses Tumorigenesis in PTEN+/− Mice , 2005, Current Biology.

[23]  V. Steele,et al.  Targeting the AKT protein kinase for cancer chemoprevention , 2007, Molecular Cancer Therapeutics.

[24]  D. Guertin,et al.  mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. , 2009, Cancer cell.

[25]  Andrew K Godwin,et al.  AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth , 2004, Oncogene.

[26]  D. V. van Aalten,et al.  Mutation of the PDK1 PH Domain Inhibits Protein Kinase B/Akt, Leading to Small Size and Insulin Resistance , 2008, Molecular and Cellular Biology.

[27]  P. Vogt,et al.  Cancer-specific mutations in phosphatidylinositol 3-kinase. , 2007, Trends in biochemical sciences.

[28]  I. Mellinghoff,et al.  Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency. , 2010, The Journal of general virology.

[29]  P. Dennis,et al.  Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. , 2004, Cancer research.

[30]  A. Prescott,et al.  Structural insights into the regulation of PDK1 by phosphoinositides and inositol phosphates , 2004, The EMBO journal.

[31]  L. Cantley,et al.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise. , 2003, Cancer cell.

[32]  Adolfo Saiardi,et al.  Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. , 2005, Cancer research.

[33]  Jorma Isola,et al.  3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. , 2009, Cancer research.

[34]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[35]  B. Vojnovic,et al.  Intramolecular and Intermolecular Interactions of Protein Kinase B Define Its Activation In Vivo , 2007, PLoS biology.

[36]  P. Pandolfi,et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.

[37]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[38]  M. Tsao,et al.  Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  C. Lindsley,et al.  The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. , 2008, Current cancer drug targets.

[40]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[41]  M. Falasca,et al.  Specificity in pleckstrin homology (PH) domain membrane targeting: a role for a phosphoinositide–protein co‐operative mechanism , 2001, FEBS letters.

[42]  G. Mills,et al.  In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  J. Dixon,et al.  PTEN: a tumour suppressor that functions as a phospholipid phosphatase. , 1999, Trends in cell biology.

[44]  R. Price,et al.  Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. , 2005, Journal of the National Cancer Institute.

[45]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[46]  Gordon B Mills,et al.  Targeting the Phosphatidylinositol 3-Kinase / Akt Pathway for Enhancing Breast Cancer Cells to Radiotherapy 1 , 2003 .

[47]  Li Zhao,et al.  Oncogenic PI3K deregulates transcription and translation , 2005, Nature Reviews Cancer.

[48]  Maria Deak,et al.  High-Resolution Structure of the Pleckstrin Homology Domain of Protein Kinase B/Akt Bound to Phosphatidylinositol (3,4,5)-Trisphosphate , 2002, Current Biology.

[49]  M. Falasca,et al.  Patterns within protein/polyphosphoinositide interactions provide specific targets for therapeutic intervention , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[50]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[51]  A. M. Riley,et al.  Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway , 2004, Oncogene.

[52]  Q. She,et al.  Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[54]  Small‐Molecule Inhibitors of PDK1 , 2008, ChemMedChem.

[55]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[56]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.